Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion

Severe acute respiratory syndrome coronavirus 2 caused a worldwide pandemia starting from March 2020. A major concern was for hematological patients, which resulted to be defenseless due to their impaired immune system and the difficulty to obtain a valid serological response to vaccination. A promising weapon is the use of anti-SARS-CoV2 monoclonal antibodies in patients with mild COVID-19 infection at high risk of progression into severe disease. Here, we reported our preliminary results of anti-SARS-CoV2 monoclonal antibodies administration for COVID-19 occurred after cell therapy. This article is protected by copyright. All rights reserved.